- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04195399
Badanie nowego leku, nirogacestatu, do leczenia guzów desmoidalnych, których nie można usunąć chirurgicznie
Badanie bezpieczeństwa, farmakokinetyki i skuteczności inhibitora y-sekretazy, nirogacestatu (PF-03084014) u dzieci i młodzieży z postępującymi, nieoperacyjnymi chirurgicznie guzami desmoidalnymi
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Przegląd badań
Status
Warunki
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To estimate the 2-year progression-free survival (PFS) rate in patients with progressive, surgically unresectable desmoid tumor treated with nirogacestat.
II. To describe the toxicities of nirogacestat in children and adolescents with desmoid tumor.
III. To characterize the pharmacokinetics (PK) of nirogacestat in children and adolescents.
SECONDARY OBJECTIVE:
I. To determine the objective tumor response rate (ORR) of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumor.
EXPLORATORY OBJECTIVES:
I. To collect blood, archival tumor samples and on-study/post-treatment tumor samples (if available) from patients enrolled on this trial to correlate various CTNNB1 and APC gene mutations and genomic signatures with tumor response and PFS.
II. To explore the effect of nirogacestat on immune cells and immunoglobulin levels in the peripheral blood.
III. To collect blood samples for banking at baseline, during treatment, and at the time of progression for future research.
IV. To compare assessment of tumor response using Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO) criteria, and T2 and volumetric changes using magnetic resonance imaging (MRI).
V. To utilize a tool developed to specifically assess patient reported outcomes (PROs) in adult patients with desmoid tumor (GOunder/DTRF DEsmoid Symptom/Impact Scale [GODDESS]) and the Patient Reported Outcomes Measurement Information System (PROMIS) to explore the relationship between PROs and tumor response and PFS.
OUTLINE:
Patients receive nirogacestat orally (PO) twice daily (BID) on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) and computed tomography (CT) or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.
After completion of study treatment, patients are followed up at 30 days.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Perth Children's Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
-
-
-
-
Christchurch, Nowa Zelandia, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nowa Zelandia, 1145
- Starship Children's Hospital
-
-
-
-
-
San Juan, Portoryko, 00926
- University Pediatric Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Stany Zjednoczone, 36604
- USA Health Strada Patient Care Center
-
-
Arizona
-
Mesa, Arizona, Stany Zjednoczone, 85202
- Banner Children's at Desert
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Stany Zjednoczone, 90242
- Kaiser Permanente Downey Medical Center
-
Loma Linda, California, Stany Zjednoczone, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Stany Zjednoczone, 90095
- Mattel Children's Hospital UCLA
-
Oakland, California, Stany Zjednoczone, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Stany Zjednoczone, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Stany Zjednoczone, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Stany Zjednoczone, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Stany Zjednoczone, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, Stany Zjednoczone, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Nemours Children's Clinic-Jacksonville
-
Orlando, Florida, Stany Zjednoczone, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Stany Zjednoczone, 32803
- AdventHealth Orlando
-
St. Petersburg, Florida, Stany Zjednoczone, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Stany Zjednoczone, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Lurie Children's Hospital-Chicago
-
Peoria, Illinois, Stany Zjednoczone, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Riley Hospital for Children
-
-
Kentucky
-
Louisville, Kentucky, Stany Zjednoczone, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Stany Zjednoczone, 70118
- Children's Hospital New Orleans
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Bethesda, Maryland, Stany Zjednoczone, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- C S Mott Children's Hospital
-
East Lansing, Michigan, Stany Zjednoczone, 48823
- Michigan State University
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Bronson Methodist Hospital
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Mercy Hospital Saint Louis
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Stany Zjednoczone, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Stany Zjednoczone, 89502
- Renown Regional Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12208
- Albany Medical Center
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stany Zjednoczone, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Syracuse, New York, Stany Zjednoczone, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Stany Zjednoczone, 45404
- Dayton Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- BI-LO Charities Children's Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Stany Zjednoczone, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Stany Zjednoczone, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78723
- Dell Children's Medical Center of Central Texas
-
Dallas, Texas, Stany Zjednoczone, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
El Paso, Texas, Stany Zjednoczone, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Cook Children's Medical Center
-
Houston, Texas, Stany Zjednoczone, 77030
- UT MD Anderson Cancer Center
-
San Antonio, Texas, Stany Zjednoczone, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84113
- Primary Children's Hospital
-
-
Virginia
-
Norfolk, Virginia, Stany Zjednoczone, 23507
- Children's Hospital of The King's Daughters
-
Roanoke, Virginia, Stany Zjednoczone, 24014
- Carilion Children's
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Children's Hospital of Wisconsin
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must be > 12 months and < 18 years of age at the time of enrollment
-
Patients must have a body surface area of > 0.3 m^2 at the time of enrollment
-
Existing or recurrent desmoid tumor that is deemed not amenable to surgery without significant morbidity and progressed by >= 10% as assessed by RECIST version (v)1.1 within the 6-month period prior to study enrollment
- Patients must have had histologic verification of the desmoid tumor
- Patients must have measurable disease by RECIST v1.1 criteria
- Patient must have received at least one prior course of systemic therapy for desmoid tumor
-
Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 50. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing performance score
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, surgery or radiotherapy prior to entering this study. Patients may not be using or anticipate using these treatments after the observed progression or within the time period stated below
- Cytotoxic chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)
- Small molecule tyrosine kinase inhibitors (e.g., sorafenib, pazopanib, imatinib), rapalogs (e.g., temsirolimus, everolimus, sirolimus) or anti estrogen therapy (e.g., tamoxifen): may not have received within 28 days prior to the first dose of study treatment
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent
- Local regional tumor directed therapy, including, but not limited to small port radiation therapy (RT), radiofrequency ablation, cryotherapy, surgery: at least 2 weeks since these therapies and all toxicity must have resolved to grade =< 1. If prior craniospinal RT or if >= 50% radiation of pelvis then >= 6 months must have elapsed. If other substantial bone marrow (BM) radiation, then >= 6 weeks must have elapsed
- Stem cell transplant (SCT): No evidence of active graft versus (vs.) host disease. For allogeneic SCT, >= 6 months must have elapsed
- No prior gamma-secretase, Notch or beta-catenin inhibitor
- Investigational drugs: must not have received investigational drug within 4 weeks of study entry, and all toxicities related to prior therapy must be resolved to grade =< 1 or baseline
-
Concomitant Medication Restrictions
- Growth factor(s): must not have received within 1 week of entry onto this study
- Patients who are currently receiving drugs that are strong inducers or moderate or strong inhibitors of CYP3A4 are not eligible. Strong inducers or moderate or strong inhibitors of CYP3A4 are not allowed from 14 days prior to enrollment to the end of protocol therapy. Note: CYP3A4 inducing anti-epileptic drugs on a stable dose, are allowed
- Must not be receiving non-steroidal anti-inflammatory drugs (NSAIDs) as treatment for desmoid tumor after the observed progression and patient agrees to not use NSAIDs while on study. Occasional use (defined as =< 3 times per week) for treatment of pain is permitted
-
Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment)
-
Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to enrollment)
-
Hemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to enrollment)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows (within 7 days prior to enrollment):
- Age: Maximum serum creatinine (mg/dL)
- Age: 1 to < 2 years; Maximum serum creatinine (mg/dL): 0.6 (male and female)
- Age: 2 to < 6 years; Maximum serum creatinine (mg/dL): 0.8 (male and female)
- Age: 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male and female)
- Age: 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male and female)
- Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
- Age: >= 16 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
-
Adequate liver function defined as:
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (unless secondary to previously diagnosed Gilbert's syndrome) (within 7 days prior to enrollment)
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L (within 7 days prior to enrollment)
-
Adequate cardiac function defined as:
- Corrected QT (QTc) interval < 470 ms
- No history of congenital or acquired prolonged QTc syndrome
- No history of clinically significant cardiac arrhythmias, congestive heart failure, stroke or myocardial infarction within 6 months prior to study entry
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Active or chronic infection within 7 days prior to study entry
-
Presence of non-healing fracture
- Note: patients with pathologic fracture related to tumor are eligible
-
Use of corticosteroids within 21 days of enrollment, except in the following situations:
- Physiologic steroid replacement for adrenal insufficiency
- Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption
- Short course (=< 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen), or exacerbation of asthma
-
Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication, prior surgical procedures affecting absorption (e.g., gastric bypass), malabsorption syndrome, and active peptic ulcer disease)
-
Patients with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
-
Known active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
-
Patients with a prior history of malignancy, with the exceptions of desmoid tumor(s) and non-melanoma skin cancer, who are not in remission for more than 3 years
-
Patients who are unable to swallow tablets. Tablets must not be crushed or chewed. Administration of nirogacestat via gastrostomy tube or nasogastric tube is not allowed
-
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
-
Sexually active female patients of reproductive potential who have not agreed to use 1 method of highly effective contraceptive (including copper-containing intrauterine device, condom with spermicidal foam/gel/film/cream/suppository, bilateral tubal ligation, established use of inserted, injected or implanted hormonal method of contraception, abstinence, or male sterilization) for the duration of their study participation and for at least 6 months after last dose of nirogacestat. A second form of contraception (i.e. barrier method) is required for patients who are using hormonal contraception as nirogacestat may reduce the efficacy of hormonal contraceptives
-
Sexually active male patients of reproductive potential who have not agreed to use a condom and their female partner who have not agreed to use one of the highly effective methods of contraception mentioned above during treatment and for at least 90 days after the last dose of nirogacestat
-
Female patients who are breastfeeding
-
Female patients who are pregnant. These patients are excluded because there is no available information regarding the effects of nirogacestat on the developing human fetus and inhibition of gamma-secretase is known to be teratogenic
-
Female patients of childbearing potential unless a negative pregnancy test result has been obtained
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment (nirogacestat)
Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and CT or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study. |
Ancillary studies
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Undergo ECHO
Inne nazwy:
Undergo x-ray
Inne nazwy:
Given PO
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free survival (PFS)
Ramy czasowe: Up to 2 years from study entry
|
The Kaplan-Meier method will be used to estimate the 2-year PFS defined as the time from study entry until disease progression or death from any cause. |
Up to 2 years from study entry
|
|
Percentage of patients experiencing grade 3+ adverse events (AE)
Ramy czasowe: Up to 6 years from study entry
|
Percentage of patients experiencing grade 3 or higher AEs will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All grade 1 and 2 toxicities observed in > 5% of participants and deemed related to study drug will be reported. |
Up to 6 years from study entry
|
|
Pharmacokinetic (PK) parameter: systemic exposure
Ramy czasowe: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
|
PK parameter: drug clearance
Ramy czasowe: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
|
PK parameter: half-life
Ramy czasowe: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective response rate
Ramy czasowe: Up to 24 months
|
Defined by the rate of a complete response or partial response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to 24 months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
CTNNB1 and APC gene mutations and genomic signatures
Ramy czasowe: Up to 2 years
|
The chi-square test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with tumor response, and the long-rank test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with PFS. |
Up to 2 years
|
|
Changes in the levels of each of the lymphocyte subsets and immunoglobulins
Ramy czasowe: Up to 2 years
|
Lymphocyte subsets include CD3 (total T cells), CD3+CD4+ (T helper cells), CD3+CD8+ (T cytotoxic cells), CD3+HLA-DR+ (activated T cells) percentages and absolute counts and CD4:CD8 ratio. The chi-square test will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with tumor response, and the Cox regression will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with PFS. |
Up to 2 years
|
|
Response assessments by the RECIST criteria
Ramy czasowe: Up to 2 years
|
Assesses tumor response based primarily on changes in measurable tumor lesions on imaging using RECIST 1.1. |
Up to 2 years
|
|
Response assessment by the World Health Organization (WHO) criteria
Ramy czasowe: Up to cycle 2 years
|
Assesses tumor response using the product of two perpendicular tumor measurements according to the WHO criteria. |
Up to cycle 2 years
|
|
Patient reported outcomes (PROs)
Ramy czasowe: Up to 2 years
|
The chi-square test will be used to assess the correlation of PROs summary scores with tumor response, and the Cox regression will be used to assess the correlation of PROs summary scores with PFS. Correlation between PRO summary scores using Patient Reported Outcomes Measurement Information System and GOunder/DTRF DEsmoid Symptom/Impact Scale will be assessed by performing inferences on the Pearson correlation coefficients. |
Up to 2 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Fariba Navid, Children's Oncology Group
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory, tkanka łączna i miękka
- Nowotwory, tkanka łączna
- Nowotwory, tkanka włóknista
- Włókniak
- Guzy desmoidalne
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Zjawiska fizyczne
- Sprzęt i materiały eksploatacyjne
- Techniki chemii, analityczne
- Analiza widma
- Zjawiska elektromagnetyczne
- Zjawiska magnetyczne
- Promieniowanie elektromagnetyczne
- Promieniowanie
- Promieniowanie, jonizujące
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Promieniowanie rentgenowskie
- Phantoms, obrazowanie
- nirogacestat
Inne numery identyfikacyjne badania
- ARST1921
- U10CA180886 (Grant/umowa NIH USA)
- ARST1921 (Inny identyfikator: CTEP)
- NCI-2019-07498 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- ARST1921 (Inny identyfikator: Children's Oncology Group)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .